The stock rate is going above to its 52 week low with 17.18% and lagging behind from its 52 week high with -71.98%. The stock cost is trading downbeat from its 200 days moving average with -8.93% and up from 50 days moving average with 4.50%.
Arca Biopharma Inc (NASDAQ: ABIO), just recently specified financial outcomes for the quarter ended September 30, 2019.
Bottom line was $1.2 M, or $0.76 per share, for the 3rd quarter of 2019 contrast to $1.6 M, or $2.06 per share, for the 3rd quarter of 2018.
Research study and development (R&D) expenses for the three months ended September 30, 2019 were $0.3 M contrast to $0.7 M for the corresponding period of 2018.
Money and cash equivalents were $9.6 M as of September 30, 2019, contrast to $6.6 M since December 31, 2018.
Arca Biopharma Inc (ABIO) stocks market capitalization came to $9.28 M and total 1.62 M exceptional shares. The stock has a 52-week highest rate of $20.45 and its 52-week most affordable cost was called at $4.89. During last trade, its optimum trading price was signed up $6.1 and its the minimum trading rate was kept in mind $5.7.
Overall operating costs for the 3 months ended September 30, 2019 were $1.2 M contrast to $1.7 M for the matching period of 2018.
On Yesterday Arca Biopharma Inc (NASDAQ: ABIO) has actually revealed a down move of -3.7% and traded the recent trade at $5.73. The trading volume is taped to 42.03 K shares as compared to typical traded volume of 50.1 K shares.
General and administrative (G&A) expenses were reasonably unchanged at $0.9 M for both the three months ended September 30, 2019 and 2018.